10x Genomics, Inc. (TXG)

NASDAQ: TXG · IEX Real-Time Price · USD
37.53
+0.64 (1.73%)
At close: Mar 28, 2024, 4:00 PM
37.44
-0.09 (-0.24%)
After-hours: Mar 28, 2024, 7:53 PM EDT

Company Description

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific.

The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell.

The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis.

It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014.

10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

10x Genomics, Inc.
10x Genomics logo
Country United States
Founded 2012
IPO Date Sep 12, 2019
Industry Health Information Services
Sector Healthcare
Employees 1,259
CEO Dr. Serge Saxonov Ph.D.

Contact Details

Address:
6230 Stoneridge Mall Road
Pleasanton, California 94588
United States
Phone (925) 401-7300
Website 10xgenomics.com

Stock Details

Ticker Symbol TXG
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $39.00
CIK Code 0001770787
CUSIP Number 88025U109
ISIN Number US88025U1097
Employer ID 45-5614458
SIC Code 3826

Key Executives

Name Position
Dr. Serge Saxonov Ph.D. Co-Founder, Chief Executive Officer and Director
Dr. Benjamin J. Hindson Ph.D. Co-Founder, President, Chief Scientific Officer and Director
Justin J. McAnear Chief Financial Officer
Eric S. Whitaker Esq. Chief Legal Officer
Michael Schnall-Levin Founding Scientist and Chief Technology Officer
Cassie Corneau Manager of Investor Relations and Strategic Finance
Rebecca Port Chief People Officer
James Bryant Director of Legal
Nikhil Rao Director of Product Management
Florian Baumgartner Senior Product Manager

Latest SEC Filings

Date Type Title
Mar 4, 2024 144 Filing
Feb 22, 2024 144 Filing
Feb 22, 2024 144 Filing
Feb 22, 2024 144 Filing
Feb 15, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 15, 2024 10-K Annual Report
Feb 15, 2024 8-K Current Report
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 31, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals